Alethia Biotherapeutics raises $2.2 million in financing
Yves Cornellier, president and CEO of Alethia, said: “We are thankful for the continuous support of GO Capital, BDC Venture Capital and Epicentre Technologies. This new investment will
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.